Daily cyclophosphamide for scleroderma: are patients with the most to gain underrepresented in this trial?

Am J Respir Crit Care Med. 2007 Nov 15;176(10):952-3. doi: 10.1164/rccm.200708-1185ED.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Cyclophosphamide / administration & dosage*
  • Drug Administration Schedule
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Patient Selection
  • Pulmonary Fibrosis / drug therapy*
  • Pulmonary Fibrosis / etiology
  • Scleroderma, Systemic / complications
  • Scleroderma, Systemic / drug therapy*
  • Treatment Outcome
  • Vital Capacity

Substances

  • Immunosuppressive Agents
  • Cyclophosphamide